Company Description
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials.
The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye.
It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases.
The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.
Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 19, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 170 |
| CEO | Ian Smith |
Contact Details
Address: 45 Wiggins Avenue Bedford, Massachusetts 01730 United States | |
| Phone | 781 430 8200 |
| Website | stoketherapeutics.com |
Stock Details
| Ticker Symbol | STOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 1623526 |
| CUSIP Number | 86150R107 |
| ISIN Number | US86150R1077 |
| Employer ID | 47-1144582 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ian F. Smith A.C.A., C.P.A. | Chief Executive Officer and Director |
| Dr. Adrian R. Krainer Ph.D. | Co-Founder and Independent Director |
| Thomas Edward Leggett | Chief Financial Officer |
| Dr. Edward M. Kaye M.D., Ph.D. | Advisor and Director |
| Jason Hoitt | Chief Patient Officer |
| Isabel Aznarez Ph.D. | Co-Founder and Chief Technology Officer |
| Dr. Thomas McCauley Ph.D. | Chief Scientific Officer |
| Jonathan Allan J.D. | Corporate Secretary, Compliance Officer and General Counsel |
| Susan Willson | Vice President of Corporate Communications |
| Sara Den Besten | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 6, 2026 | SCHEDULE 13G/A | Filing |
| Aug 3, 2026 | 8-K | Current Report |
| Aug 3, 2026 | 424B5 | Filing |
| Aug 3, 2026 | 144 | Filing |
| Aug 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 3, 2026 | 10-Q | Quarterly Report |
| Aug 3, 2026 | 8-K | Current Report |
| Jul 1, 2026 | 144 | Filing |
| Jun 30, 2026 | 8-K | Current Report |
| Jun 16, 2026 | 144 | Filing |